News

GB Sciences’ Brain Nurse Explores the New and Exciting World of Medical Cannabis

Shared Content
Written by Shared Content

Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka “the brain nurse”, provides a “tour guide through the lobes” as she writes a series of popular science cannabis blogs for GB Sciences.

LAS VEGAS, Oct. 25, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) introduces “the brain nurse”, Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has learned the value of questions.  When she first heard patients extolling the virtues of cannabis for serious medical conditions, such as Parkinson’s as well as difficult to treat ongoing conditions such as chronic pain, she got curious.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8308954-gb-sciences-meredith-patterson-cannabis-brain-nurse/

It’d been pretty clear to Meredith for some time that the traditional medical system was broken.  It’s the one where the patient goes to the doc and the doc, pressed for time, diagnoses without listening to the patient.  As a nurse, you are taught to listen to the patient and in doing so become an advocate for the patient.  However, a nurse can’t prescribe.  This is unlike the world of medical marijuana one where self-dosing is possible.  At this point, Meredith steps in as advocate and teacher making hard cannabis science accessible to the masses.  She puts the science in a language that a patient can understand and is therefore better educated to prescribe for one’s self.

Meredith now writes a series of blogs in which she explains all the benefits, dispels the misconceptions and helps put minds at ease about a drug that’s been vilified for so long. What follows is her first in a series of blogs which focus on CBD.

How CBD Works as a Multi-Tasker

In the wake of the rescheduling of CBD from a Schedule 1 (like heroin) to a Schedule 5 (like Sudafed), I went on a research quest to discover more about the popular uses of CBD, the so-called non-psychoactive component of cannabis.  The second CBD dispensary I visited on my research was abuzz with activity on a hot Friday afternoon.

Inside were three employees and the store owner, a quiet-spoken young man who briefed me on his wares – vapes, buds, tinctures, gummy candies, even coffees infused with CBD.  A few minutes later a camera man from a local television station showed up along with a high school student and his mother to film their story “from drugs to CBD.”

“This is our best-seller, “said one of the sales clerks, pointing to a brown vial called “Calm”.  Also popular were formulas called “Focus “and “Energy” alongside another tincture promoting sleep.  No surprise here – relief from stress, anxiety, distraction, and insomnia are the most common complaints I hear about every single day.  Medicine doesn’t have good answers for these problems outside of a heavy reliance on prescription medications and sleep-apnea tests.

The energy in the CBD store was palpable as more customers crowded inside.  The experience reminded me of shopping at the early Apple stores, the shiny objects beckoning from their neatly-arranged positions under glass counters.

The products are pricey, $30-$200 for a one-month-supply bottle.  And the unflavored CBD oil I sampled can be kindly described as earthy, as if a plant stalk had been chopped up and pulsed in a food processor.   (The shopkeeper told me “it’s an acquired taste.”)  But business was brisk and few customers left empty-handed.

This CBD compound can interact in many processes of the human brain and body.  That explains how it can be so many things for so many people.  So my research continues.

GB Sciences’ Chairman and CEO John Poss comments, “Meredith is an important part of the GB team.  Her experience and intellectual curiosity bring to the public a better understanding of the medical foundations of cannabis.”

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Meredith Patterson, RN, BSN, CRRN

Meredith is a registered nurse with over 25 years of neuroscience nursing experience in a variety of settings including intensive care, head injury acute care rehabilitation, sub-acute and dementia care. She has authored numerous presentations and continuing education classes for nursing professionals and is a frequent presenter for community and professional audiences including the University of Texas Health Science Center, Scott and White Hospital, Texas State University and the annual Alzheimer’s Symposium in New Braunfels.

Meredith is a graduate of the University of Texas Health Science Center in San Antonio and she is certified in rehabilitation nursing. She is past president of the Association of Rehabilitation Nurses of San Antonio and has served as a reviewer for the journal of the Association of Neuroscience Nurses.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

About the author

Shared Content

Shared Content

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.